Unaudited financial results for the quarter and nine months ended December 31, 2025.
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech reported weaker Q3 standalone results with revenue from operations falling to ₹114.24 crore from ₹146.25 crore a year ago (~22% YoY decline), and profit after tax dropping to ₹11.76 crore from ₹35.00 crore (~66% YoY decline). The decline was mainly because the property segment had no sales this quarter versus ₹38.38 crore a year ago (one-time property divestments); the core bulk drugs/chemicals business actually grew to ₹113.29 crore from ₹102.59 crore. For the nine-month period, consolidated revenue grew strongly to ₹403.85 crore (~22.5% YoY) and consolidated PAT rose to ₹51.65 crore from ₹43.08 crore. An exceptional charge of ₹2.11 crore (standalone) was booked this quarter for additional gratuity liability arising from the new Labour Codes notified in November 2025. The company also completed the slump sale of its Environment Division to a wholly-owned subsidiary for ₹19 crore on October 1, 2025. Auditors SRBC & Co LLP issued a clean limited review report with no qualifications.
The headline Q3 numbers look weak YoY but the decline is largely due to the absence of one-time property sale income; the operating bulk drugs business remains healthy and is the main driver of 9M consolidated revenue crossing 20% YoY growth. Near-term sentiment may be cautious given the exceptional Labour Codes charge, but underlying core business momentum appears positive for shareholders.